Powell Abigail E, Zhang Kaiming, Sanyal Mrinmoy, Tang Shaogeng, Weidenbacher Payton A, Li Shanshan, Pham Tho D, Pak John E, Chiu Wah, Kim Peter S
Department of Biochemistry & Stanford ChEM-H, Stanford University, Stanford, California 94305, United States.
Department of Bioengineering & James H. Clark Center, Stanford University, Stanford, California 94305, United States.
ACS Cent Sci. 2021 Jan 27;7(1):183-199. doi: 10.1021/acscentsci.0c01405. Epub 2021 Jan 5.
The development of a safe and effective SARS-CoV-2 vaccine is a public health priority. We designed subunit vaccine candidates using self-assembling ferritin nanoparticles displaying one of two multimerized SARS-CoV-2 spikes: full-length ectodomain (S-Fer) or a C-terminal 70 amino-acid deletion (SΔC-Fer). Ferritin is an attractive nanoparticle platform for production of vaccines, and ferritin-based vaccines have been investigated in humans in two separate clinical trials. We confirmed proper folding and antigenicity of spike on the surface of ferritin by cryo-EM and binding to conformation-specific monoclonal antibodies. After a single immunization of mice with either of the two spike ferritin particles, a lentiviral SARS-CoV-2 pseudovirus assay revealed mean neutralizing antibody titers at least 2-fold greater than those in convalescent plasma from COVID-19 patients. Additionally, a single dose of SΔC-Fer elicited significantly higher neutralizing responses as compared to immunization with the spike receptor binding domain (RBD) monomer or spike ectodomain trimer alone. After a second dose, mice immunized with SΔC-Fer exhibited higher neutralizing titers than all other groups. Taken together, these results demonstrate that multivalent presentation of SARS-CoV-2 spike on ferritin can notably enhance elicitation of neutralizing antibodies, thus constituting a viable strategy for single-dose vaccination against COVID-19.
开发一种安全有效的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗是公共卫生的优先事项。我们设计了亚单位疫苗候选物,使用自组装铁蛋白纳米颗粒展示两种多聚化的SARS-CoV-2刺突蛋白之一:全长胞外结构域(S-Fer)或C末端缺失70个氨基酸(SΔC-Fer)。铁蛋白是一种用于生产疫苗的有吸引力的纳米颗粒平台,基于铁蛋白的疫苗已在两项独立的临床试验中在人体进行了研究。我们通过冷冻电镜证实了铁蛋白表面刺突蛋白的正确折叠和抗原性,并证实其与构象特异性单克隆抗体结合。用两种刺突铁蛋白颗粒中的任何一种对小鼠进行单次免疫后,慢病毒SARS-CoV-2假病毒试验显示,平均中和抗体滴度比COVID-19患者康复期血浆中的滴度至少高2倍。此外,与单独用刺突受体结合域(RBD)单体或刺突胞外结构域三聚体免疫相比,单剂量的SΔC-Fer引发的中和反应明显更高。第二次给药后,用SΔC-Fer免疫的小鼠表现出比所有其他组更高的中和滴度。综上所述,这些结果表明,SARS-CoV-2刺突蛋白在铁蛋白上的多价呈递可以显著增强中和抗体的诱导,从而构成一种可行的单剂量接种COVID-19疫苗的策略。